Neo Ivy Capital Management Acquires Shares of 100,780 TG Therapeutics, Inc. (NASDAQ:TGTX)

Neo Ivy Capital Management purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 100,780 shares of the biopharmaceutical company's stock, valued at approximately $2,358,000. Neo Ivy Capital Management owned 0.06% of TG Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. NBC Securities Inc. lifted its stake in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of TG Therapeutics in the second quarter worth $35,000. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 849 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in TG Therapeutics during the third quarter valued at $53,000. Finally, Values First Advisors Inc. purchased a new position in TG Therapeutics during the third quarter worth about $58,000. 58.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TGTX shares. StockNews.com downgraded TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, December 6th. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. TD Cowen began coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective for the company. Finally, HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $40.67.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is owned by insiders.

TG Therapeutics Trading Down 0.2 %

NASDAQ TGTX traded down $0.05 during trading on Wednesday, hitting $31.62. 782,927 shares of the company's stock traded hands, compared to its average volume of 3,614,037. The stock has a fifty day moving average of $28.01 and a two-hundred day moving average of $23.14. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84. The firm has a market cap of $4.92 billion, a P/E ratio of -316.67 and a beta of 2.25. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million during the quarter, compared to analysts' expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics's revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 EPS. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.